Back to search results

CHANCES Study: Understanding Blood Changes in Cancer Patients

This study, called CHANCES, is looking at how certain changes in your blood, called clonal hematopoiesis (CH), and new blood cancers (therapy-emergent myeloid neoplasms or TMN) might develop in people with ovarian, fallopian tube, peritoneal, or other solid cancers. Researchers want to understand why these blood changes happen, especially in patients who have received platinum-based chemotherapy or PARP inhibitors. They are trying to find out if there are specific risk factors or genetic reasons for developing these conditions. You might be able to join if you have or had one of these cancers and have received or will receive at least 5 cycles of platinum-based chemotherapy, or if you've been exposed to a PARP inhibitor for at least 4 months. The study aims to track these changes for up to 5 years.

Study design
This is an observational study involving 2000 participants. It means researchers will watch and collect information without giving you a specific treatment.
What's involved
You would provide blood samples and complete surveys. Your medical records will also be reviewed.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed through study completion, which could be up to 5 years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06295965

Clonal Hematopoiesis and Therapy-Emergent Myeloid Neoplasms in Patients With Cancers, CHANCES Study

Recruiting
Not specifiedAll AgesObservational
University of Washington
~2,000 participants
Updated 2026-04-17 on ClinicalTrials.gov
What's tested:Non-Interventional Study

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Determine the correlation between baseline TP53m VAF in blood with CH expansion in OC patients
Measured over Through study completion, up to 5 years
+2 more outcomes measured

Conditions

Recurrent Fallopian Tube Carcinoma
Recurrent Ovarian Carcinoma
Recurrent Primary Peritoneal Carcinoma
Recurrent Malignant Solid Neoplasm
Clonal Cytopenia of Undetermined Significance
Clonal Hematopoiesis
Idiopathic Cytopenia of Undetermined Significance
Non-Neoplastic Hematopoietic and Lymphoid Cell Disorder
Ovarian Carcinoma
Myeloid Neoplasm Post Cytotoxic Therapy

Explore related trials

Clonal HematopoiesisMyeloid NeoplasmOvarian CarcinomaSolid Neoplasm

Where it's being run

1 sites across 1 states
Washington1

Study leadership

  • Elizabeth Swisher · PRINCIPAL_INVESTIGATOR · Fred Hutch/University of Washington Cancer Consortium

Who to contact

Swisher Lab Research Coordinators
[email protected]
206-616-8927
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Subjects who have or have had ovarian, peritoneal, or fallopian tube carcinoma who have a life expectancy of greater than 6 months and:
Have completed or plan to complete at least 5 cycles of platinum-based chemotherapy
Subjects who have or have had a solid tumor diagnosis and any of the following:
At least 4 months of exposure to a PARP inhibitor
Diagnosis of a blood disorder including, but not limited to, clonal hematopoiesis of indeterminate potential, cytopenia of unknown significance, or therapy-related myeloid neoplasm

Exclusion

Individuals with a life expectancy of less than 6 months

What this trial measures

  • Determine the correlation between baseline TP53m VAF in blood with CH expansion in OC patientsThrough study completion, up to 5 years
  • Identify risk of TMN for OC survivors with and without TP53m CH treated with platinum chemotherapy and PARP inhibitorsThrough study completion, up to 5 years

    Measurement Tool: will measure by BM biopsy confirmation done by local hematologist

  • Define the trajectories of clonal evolution and mechanisms of transformation from non-cancerous TP53m to TMNThrough study completion, up to 5 years

    Measurement Tool: the variant allele fraction of the blood clone